Press Release
View printer-friendly version
Materialise Reports First Quarter 2023 Results
LEUVEN,
Highlights – First Quarter 2023
- Total revenue increased 24.4% to 65,886 kEUR compared to 52,961 kEUR for the first quarter of 2022.
- Total deferred revenues from annual software sales and maintenance fees increased by 1,728 kEUR this quarter to 44,508 kEUR.
- Adjusted EBITDA increased to 10,310 kEUR for the first quarter of 2023 from 5,443 kEUR for the 2022 period.
- Net profit for the first quarter of 2023 was 3,715 kEUR, or
0.06 EUR per diluted share, compared to 127 kEUR, or0.00 EUR per diluted share, for the 2022 period.
Executive Chairman
First Quarter 2023 Results
Total revenue for the first quarter of 2023 increased 24.4% to 65,886 kEUR from 52,961 kEUR for the first quarter of 2022. Adjusted EBITDA increased to 10,310 kEUR for the first quarter of 2023 from 5,443 kEUR for the 2022 period. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the first quarter of 2023 was 15.6%, compared to 10.3% for the first quarter of 2022.
Revenue from
Revenue from our Materialise Medical segment increased 32.5% to 24,317 kEUR for the first quarter of 2023 compared to 18,347 kEUR for the same period in 2022. Segment Adjusted EBITDA increased to 7,348 kEUR for the first quarter of 2023 compared to 3,227 kEUR while the segment Adjusted EBITDA margin grew to 30.2% compared to 17.6% for the first quarter of 2022.
Revenue from our Materialise Manufacturing segment increased 25.2% to 30,219 kEUR for the first quarter of 2023 from 24,131 kEUR for the first quarter of 2022. Segment Adjusted EBITDA increased to 3,189 kEUR from 2,613 kEUR while the segment Adjusted EBITDA margin was 10.6% compared to 10.8% for the first quarter of 2022.
Gross profit grew to 36,837 kEUR compared to 28,884 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 55.9% compared to 54.5% for the first quarter of 2022.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 8.7% to 32,358 kEUR for the first quarter of 2023 from 29,774 kEUR for the first quarter of 2022.
Net other operating income was 519 kEUR compared to 938 kEUR for the first quarter of 2022.
Operating result amounted to 4,998 kEUR compared to 49 kEUR for the first quarter of 2022.
Net financial result was (566) kEUR compared to 376 kEUR for the first quarter of 2022.
The first quarter of 2023 contained income tax expenses of (718) kEUR, compared to (298) kEUR in the first quarter of 2022.
As a result of the above, net profit for the first quarter of 2023 was 3,715 kEUR, compared to 127 kEUR for the same period in 2022. Total comprehensive income for the first quarter of 2023, which includes exchange differences on translation of foreign operations, was 4,490 kEUR compared to 1,543 kEUR for the 2022 period.
At
Cash flow from operating activities for the first quarter of 2023 decreased to 11,044 kEUR from 11,111 kEUR for the same period in 2022. Total capital expenditures for the first quarter of 2023 amounted to 3,271 kEUR.
Net shareholders’ equity at
2023 Guidance
Executive Chairman
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2023 on
To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call.
The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website.
About Materialise
Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our current estimates for fiscal 2023 revenue and Adjusted EBITDA, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the ongoing military conflict between
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited) |
||||||
for the three months ended |
||||||
In '000 |
2023 |
2023 |
2022 |
|||
U.S.$ | € | € | ||||
Revenue |
71,651 |
65,886 |
52,961 |
|||
Cost of Sales |
(31,591) |
(29,049) |
(24,078) |
|||
Gross Profit |
40,060 |
36,837 |
28,884 |
|||
Gross profit as % of revenue |
55.9% |
55.9% |
54.5% |
|||
Research and development expenses |
(9,802) |
(9,014) |
(7,814) |
|||
Sales and marketing expenses |
(15,539) |
(14,288) |
(13,515) |
|||
General and administrative expenses |
(9,848) |
(9,056) |
(8,444) |
|||
Net other operating income (expenses) |
565 |
519 |
938 |
|||
Operating (loss) profit |
5,436 |
4,998 |
49 |
|||
Financial expenses |
(1,495) |
(1,375) |
(1,289) |
|||
Financial income |
880 |
809 |
1,665 |
|||
Share in loss of joint venture |
- |
- |
- |
|||
(Loss) profit before taxes |
4,821 |
4,432 |
425 |
|||
Income Taxes |
(780) |
(718) |
(298) |
|||
Net (loss) profit for the period |
4,041 |
3,715 |
127 |
|||
Net (loss) profit attributable to: |
- |
|||||
The owners of the parent |
4,047 |
3,721 |
134 |
|||
Non-controlling interest |
(7) |
(7) |
(7) |
|||
Earning per share attributable to owners of the parent | ||||||
Basic |
0.07 |
0.06 |
0.00 |
|||
Diluted |
0.07 |
0.06 |
0.00 |
|||
Weighted average basic shares outstanding |
59,067 |
59,067 |
59,064 |
|||
Weighted average diluted shares outstanding |
59,070 |
59,070 |
59,102 |
Consolidated statements of comprehensive income (Unaudited) |
|||||||
for the three months ended |
|||||||
In 000€ |
2023 |
2023 |
2022 |
||||
U.S.$ | € | € | |||||
Net profit (loss) for the period |
4,041 |
3,715 |
127 |
||||
Other comprehensive income | |||||||
Recycling | |||||||
Exchange difference on translation of foreign operations |
843 |
776 |
1,416 |
||||
Non-recycling | |||||||
Fair value adjustments through OCI - Equity instruments |
- |
- |
- |
||||
Other comprehensive income (loss), net of taxes |
843 |
776 |
1,416 |
||||
Total comprehensive income (loss) for the year, net of taxes |
4,883 |
4,490 |
1,543 |
||||
Total comprehensive income (loss) attributable to: | |||||||
The owners of the parent |
4,890 |
4,496 |
1,549 |
||||
Non-controlling interests |
(6) |
(6) |
(7) |
Consolidated statement of financial position (Unaudited) |
||||
As of |
As of |
|||
In 000€ |
2023 |
2022 |
||
Assets | ||||
Non-current assets | ||||
44,196 |
44,155 |
|||
Intangible assets |
36,944 |
37,875 |
||
Property, plant & equipment |
94,462 |
94,276 |
||
Right-of-Use assets |
8,323 |
8,420 |
||
Investments in joint ventures |
- |
- |
||
Deferred tax assets |
1,208 |
1,186 |
||
Investments in convertible loans |
3,555 |
3,494 |
||
Investments in non-listed equity instruments |
307 |
307 |
||
Other non-current assets |
5,414 |
5,136 |
||
Total non-current assets |
194,409 |
194,847 |
||
Current assets | ||||
Inventories |
15,810 |
16,081 |
||
Trade receivables |
47,780 |
51,043 |
||
Other current assets |
8,114 |
8,424 |
||
Cash and cash equivalents |
141,720 |
140,867 |
||
Total current assets |
213,423 |
216,414 |
||
Total assets |
407,833 |
411,262 |
As of |
As of |
|||
In 000€ |
2023 |
2022 |
||
Equity and liabilities | ||||
Equity | ||||
Share capital |
4,487 |
4,487 |
||
Share premium |
233,895 |
233,895 |
||
Retained earnings and other reserves |
(5,097) |
(9,427) |
||
Equity attributable to the owners of the parent |
233,285 |
228,955 |
||
Non-controlling interest |
(34) |
(28) |
||
Total equity |
233,251 |
228,928 |
||
Non-current liabilities | ||||
Loans & borrowings |
51,035 |
55,873 |
||
Lease liabilities |
4,964 |
5,147 |
||
Deferred tax liabilities |
4,167 |
4,312 |
||
Deferred income |
8,858 |
9,277 |
||
Other non-current liabilities |
504 |
1,611 |
||
Total non-current liabilities |
69,528 |
76,220 |
||
Current liabilities | ||||
Loans & borrowings |
16,328 |
17,058 |
||
Lease liabilities |
2,924 |
2,902 |
||
Trade payables |
23,776 |
23,230 |
||
Tax payables |
1,922 |
1,246 |
||
Deferred income |
43,474 |
41,721 |
||
Other current liabilities |
16,630 |
19,957 |
||
Total current liabilities |
105,054 |
106,114 |
||
Total equity and liabilities |
407,833 |
411,262 |
Consolidated statement of cash flows (Unaudited) |
||||
for the three months ended |
||||
In 000€ |
2023 |
2022 |
||
Operating activities | ||||
Net (loss) profit for the period |
3,715 |
127 |
||
Non-cash and operational adjustments | ||||
Depreciation of property plant & equipment |
3,637 |
3,840 |
||
Amortization of intangible assets |
1,674 |
1,602 |
||
Impairment of goodwill and intangible assets |
- |
- |
||
Share-based payment expense |
- |
(48) |
||
Loss (gain) on disposal of intangible assets and property, plant & equipment |
(22) |
(18) |
||
Movement in provisions |
(618) |
2 |
||
Movement reserve for bad debt and slow moving inventory |
109 |
130 |
||
Financial income |
(767) |
(1,618) |
||
Financial expense |
1,375 |
1,237 |
||
Impact of foreign currencies |
6 |
(28) |
||
(Deferred) income taxes |
717 |
302 |
||
Working capital adjustments |
850 |
5,923 |
||
Decrease (increase) in trade receivables and other receivables |
3,363 |
4,506 |
||
Decrease (increase) in inventories and contracts in progress |
262 |
(1,357) |
||
Increase (decrease) in deferred revenue |
1,368 |
3,665 |
||
Increase (decrease) in trade payables and other payables |
(4,142) |
(891) |
||
Income tax paid & Interest received |
367 |
(341) |
||
Net cash flow from operating activities |
11,044 |
11,111 |
for the three months ended |
||||
In 000€ |
2023 |
2022 |
||
Investing activities | ||||
Purchase of property, plant & equipment |
(2,532) |
(2,376) |
||
Purchase of intangible assets |
(738) |
(1,123) |
||
Proceeds from the sale of property, plant & equipment & intangible assets (net) |
100 |
93 |
||
Acquisition of subsidiary (net of cash) |
- |
(27,414) |
||
Net cash flow used in investing activities |
(3,171) |
(30,820) |
||
Financing activities | ||||
Repayment of loans & borrowings |
(5,635) |
(5,969) |
||
Repayment of leases |
(859) |
(881) |
||
Interest paid |
(417) |
(515) |
||
Other financial income (expense) |
(108) |
(89) |
||
Net cash flow from (used in) financing activities |
(7,019) |
(7,452) |
||
Net increase/(decrease) of cash & cash equivalents |
854 |
(27,161) |
||
Cash & Cash equivalents at the beginning of the year |
140,867 |
196,028 |
||
Exchange rate differences on cash & cash equivalents |
(1) |
743 |
||
Cash & cash equivalents at end of the period |
141,720 |
169,610 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
|||||
for the three months ended |
|||||
In 000€ |
2023 |
2022 |
|||
Net profit (loss) for the period |
3,715 |
127 |
|||
Income taxes |
718 |
298 |
|||
Financial expenses |
1,375 |
1,289 |
|||
Financial income |
(809) |
(1,665) |
|||
Depreciation and amortization |
5,311 |
5,442 |
|||
EBITDA |
10,310 |
5,491 |
|||
Share-based compensation expense (1) |
- |
(48) |
|||
Adjusted EBITDA |
10,310 |
5,443 |
(1) | Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. |
Segment P&L (Unaudited) |
||||||||||||
In 000€ | Materialise Software |
Materialise Medical |
Materialise Manufacturing |
Total segments |
Unallocated (1) | Consolidated | ||||||
For the three months ended |
||||||||||||
Revenues |
11,350 |
24,317 |
30,219 |
65,886 |
0 |
65,886 |
||||||
Segment (adj) EBITDA |
2,427 |
7,348 |
3,189 |
12,964 |
(2,655) |
10,310 |
||||||
Segment (adj) EBITDA % |
21.4% |
30.2% |
10.6% |
19.7% |
15.6% |
|||||||
For the three months ended |
||||||||||||
Revenues |
10,483 |
18,347 |
24,131 |
52,961 |
0 |
52,961 |
||||||
Segment (adj) EBITDA |
1,932 |
3,227 |
2,613 |
7,772 |
(2,329) |
5,443 |
||||||
Segment (adj) EBITDA % |
18.4% |
17.6% |
10.8% |
14.7% |
10.3% |
(1) |
Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited) |
||||
for the three months ended |
||||
In 000€ |
2023 |
2022 |
||
Net profit (loss) for the period |
3,715 |
127 |
||
Income taxes |
718 |
298 |
||
Financial cost |
1,375 |
1,289 |
||
Financial income |
(809) |
(1,665) |
||
Operating (loss) profit |
4,998 |
49 |
||
Depreciation and amortization |
5,311 |
5,442 |
||
Corporate research and development |
722 |
816 |
||
Corporate headquarter costs |
2,640 |
2,106 |
||
Other operating income (expense) |
(707) |
(640) |
||
Segment adjusted EBITDA |
12,964 |
7,772 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005072/en/
Investor Relations
LHA
212.838.3777
hfried@lhai.com
Source: